Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Standard dose 131I therapy for hyperthyroidism caused by autonomously functioning thyroid nodules.

S C Ng Tang Fui, M N Maisey

    Clinical Endocrinology
    |January 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The role of FDG-PET in the management of non-small cell lung carcinoma.

    Annals of the Academy of Medicine, Singapore·2004
    Same author

    Positron emission tomography for urological tumours.

    BJU international·2003
    Same author

    Overview of clinical PET.

    The British journal of radiology·2003
    Same author

    Positron emission tomography in lung cancer.

    Seminars in nuclear medicine·2003
    Same author

    FDG-PET. A possible prognostic factor in head and neck cancer.

    British journal of cancer·2002
    Same author

    FDG-PET as a "metabolic biopsy" tool in thoracic lesions with indeterminate biopsy.

    European journal of nuclear medicine·2001

    A standard dose of radioactive iodine (131I) effectively treated hyperthyroidism from autonomously functioning thyroid nodules. Most patients achieved normal thyroid function after a single treatment, with a low risk of hypothyroidism.

    Area of Science:

    • Endocrinology
    • Nuclear Medicine
    • Oncology

    Background:

    • Hyperthyroidism is often caused by autonomously functioning thyroid nodules.
    • Radioiodine-131 (131I) is a common treatment for hyperthyroidism.
    • Graves' disease, another cause of hyperthyroidism, has a higher incidence of hypothyroidism after 131I therapy.

    Purpose of the Study:

    • To evaluate the efficacy and safety of a standard 15 mCi dose of 131I in treating hyperthyroidism caused by autonomously functioning thyroid nodules.
    • To compare the outcomes with radioiodine therapy for Graves' disease.

    Main Methods:

    • Thirty-one patients with hyperthyroidism and autonomously functioning thyroid nodules (confirmed by scintigram) received a single 15 mCi dose of 131I.
    • Follow-up included clinical assessment, repeat scintigraphy, and Thyrotropin Releasing Hormone (TRH) testing for up to 3 years.

    Related Experiment Videos

    Main Results:

    • Twenty-nine of thirty followed patients (96.7%) became euthyroid after a single dose of 131I.
    • Twenty-five patients (80.6%) were considered cured.
    • Only one patient developed hypothyroidism, a significantly lower rate than typically seen in Graves' disease.

    Conclusions:

    • A simplified, standard dose regimen of 131I is effective for treating hyperthyroidism due to autonomously functioning thyroid nodules.
    • This treatment approach offers a favorable safety profile with a low risk of hypothyroidism.
    • Radioiodine therapy for autonomously functioning thyroid nodules is a viable alternative to treatment for Graves' disease.